Sex Discernment and Successful Pregnancy Applications to Boost Pre-implantation Genetic Diagnosis Market

Blog Description

Pre-implantation genetic diagnosis (PGD) comprises genetic profiling of embryos before they are implanted and of oocytes before fertilization. Hence, PGD is a technique used for the detection of genetic conditions and diseases prior to the implantation of an embryo. A range of medical abnormalities can be detected by the use of PGD such as inheritable diseases, Down’s syndrome, and various physiological abnormalities. Factors such as the increasing occurrence of genetic diseases in infants and rising awareness about PGD techniques are amongst the chief factors fuelling the market for pre-implantation genetic diagnosis.

Browse the full Report of Global Preimplantation Genetic Diagnosis Market: http://www.mrrse.com/preimplantation-genetic-diagnosis-market

On the basis of test type, the market for preimplantation genetic diagnosis is segmented into PGD for chromosomal aberrations, PGD for gender selection, PGD for X-linked diseases, PGD for HLA typing, PGD for aneuploidy screening, and PGD for single gene disorders. PGD is utilized for the selection of embryos without any genetic disorders for enhanced chances of pregnancy, lower cancer disposition, and sex selection. The three prime application areas of PGD are detailed as follows:

• Monogenic Disorders: PGD is used for the detection of a wide range of monogenic disorders. These disorders are related to one particular gene only. PGD helps in the identification of embryos carrying chromosome abnormalities or genetic diseases and thus helps in eliminating the chances of having a diseased offspring. The key autosomal recessive disorders are beta-thalassemia, cystic fibrosis, spinal muscular atrophy type 1, and sickle cell disease. The most prevalent diseases include Huntington’s disease, myotonic dystrophy, and Charcot-Marie-Tooth disease. 

• Pregnancy Chances: Pre-implantation genetic profiling is a method for determining the embryo quality and for the selection of an embryo having the greatest chances of successful pregnancy. In addition, IVF pregnancies having a sperm count less than 20 mn may have a greater percentage of embryos that are chromosomally abnormal. Hence, PGD is utilized for decreasing the risks of these abnormalities. 

• Cancer Predisposition and Sex Discernment: PGD is also utilized in the diagnosis of diseases having a late onset and also presents methods of prenatal sex discernment prior to embryo implantation and is therefore also called as preimplantation sex discernment. In cases of families having a risk of X-linked diseases, the patient is presented with a single PGD assay of gender identification. This gender selection presents a solution to individuals having X-linked diseases. Some of the X-linked Mendelian diseases are hemophilia A and B and Duchenne muscular dystrophy; however, these rarely occur in females, as the offspring is not likely to inherit 2 copies of recessive alleles. 

In all, three assessments take place before the start of the PGD process to prevent inherited disorders. For the validation of the usage of PGD, gender selection takes place on the basis of the inherited condition’s seriousness, the disease treatment options, and the risk involved in the process. PGD is also occasionally utilized for the detection of a specific disability or disease such as deafness, etc. in the embryo.

Browse the full Press Release of Global Preimplantation Genetic Diagnosis Market: http://www.mrrse.com/preimplantation-genetic-diagnosis-industry

The major players operating in the preimplantation genetic diagnosis market are Genea Ltd., Genesis Genetics, Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings, PerkinElmer, Inc., Reprogenetics LLC, Reproductive Genetics Institute, and Quest Diagnostics, Inc., among others.